ATE361667T1 - Stoppen, schützen und konservieren von organen - Google Patents

Stoppen, schützen und konservieren von organen

Info

Publication number
ATE361667T1
ATE361667T1 AT00910414T AT00910414T ATE361667T1 AT E361667 T1 ATE361667 T1 AT E361667T1 AT 00910414 T AT00910414 T AT 00910414T AT 00910414 T AT00910414 T AT 00910414T AT E361667 T1 ATE361667 T1 AT E361667T1
Authority
AT
Austria
Prior art keywords
protecting
stopping
agonist
preserving organs
effective amounts
Prior art date
Application number
AT00910414T
Other languages
English (en)
Inventor
Geoffrey Dobson
Original Assignee
Hibernation Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP9414A external-priority patent/AUPP941499A0/en
Priority claimed from AUPQ4199A external-priority patent/AUPQ419999A0/en
Application filed by Hibernation Therapeutics Ltd filed Critical Hibernation Therapeutics Ltd
Application granted granted Critical
Publication of ATE361667T1 publication Critical patent/ATE361667T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331—Preservative, buffer, anticoagulant or diluent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dentistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Packages (AREA)
  • Materials For Medical Uses (AREA)
  • Saccharide Compounds (AREA)
  • Processing Of Solid Wastes (AREA)
AT00910414T 1999-03-23 2000-03-22 Stoppen, schützen und konservieren von organen ATE361667T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP9414A AUPP941499A0 (en) 1999-03-23 1999-03-23 Organ arrest, protection and preservation
AUPQ4199A AUPQ419999A0 (en) 1999-11-23 1999-11-23 Organ arrest, protection and preservation

Publications (1)

Publication Number Publication Date
ATE361667T1 true ATE361667T1 (de) 2007-06-15

Family

ID=25646014

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00910414T ATE361667T1 (de) 1999-03-23 2000-03-22 Stoppen, schützen und konservieren von organen

Country Status (17)

Country Link
US (7) US6955814B1 (de)
EP (3) EP1168912B1 (de)
JP (1) JP4949558B2 (de)
KR (1) KR20020001797A (de)
CN (1) CN1344135A (de)
AT (1) ATE361667T1 (de)
BR (1) BR0010653A (de)
CA (1) CA2364687C (de)
DE (1) DE60034778T2 (de)
ES (1) ES2287001T3 (de)
IL (1) IL145552A0 (de)
MX (1) MXPA01009552A (de)
NO (2) NO331669B1 (de)
NZ (1) NZ514515A (de)
PL (1) PL351484A1 (de)
TR (1) TR200103235T2 (de)
WO (1) WO2000056145A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL351484A1 (en) * 1999-03-23 2003-04-22 Univ James Cook Organ arrest, protection and preservation
CA2475209A1 (en) 2002-02-04 2003-08-14 Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
AUPS312602A0 (en) * 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US20040170950A1 (en) * 2002-09-12 2004-09-02 Prien Samuel D. Organ preservation apparatus and methods
AU2003291847B2 (en) * 2002-12-23 2010-12-02 Hibernation Therapeutics, A Kf Llc Organ preconditioning, arrest, protection, preservation and recovery
CA2551169A1 (en) * 2002-12-23 2004-07-08 Global Cardiac Solutions Pty Ltd Organ preconditioning, arrest, protection, preservation and recovery
CN101453984A (zh) * 2006-03-31 2009-06-10 艾登欧比公司 使用腺苷和肌苷组合用于诊断和治疗的组合物、方法和试剂盒
CN104107431A (zh) * 2006-05-29 2014-10-22 低温药理有限公司 改善的组织维持
AU2006345361B2 (en) * 2006-05-29 2014-04-10 Hibernation Therapeutics, A Kf Llc Improved tissue maintenance
US7811549B2 (en) * 2006-07-05 2010-10-12 Adenobio N.V. Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
JP2009544628A (ja) * 2006-07-25 2009-12-17 ハイバーネイション セラピューティクス リミテッド 外傷治療
EP2173353B1 (de) * 2007-03-02 2015-05-06 Hibernation Therapeutics, a KF LLC Zusammensetzung mit Adenosin und Lignocain
US20080269109A1 (en) * 2007-04-30 2008-10-30 Becker Lance B System and method of resuscitation of a mammal
US20100256083A1 (en) * 2007-07-25 2010-10-07 Hibernation Therapeutics Limited Organ protection, preservation and recovery
DE102007035642A1 (de) * 2007-07-30 2009-02-12 Grietje Beck Substanzen zur Protektion von Zellen und Geweben gegen Schädigung durch ungünstige Bedingungen
US20090185973A1 (en) * 2008-01-22 2009-07-23 Adenobio N.V. Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
US20120046354A1 (en) * 2010-08-18 2012-02-23 Ehrenpreis Eli D Anti-oxidant lozenges for the prevention and treatment of radiation induced mucositis, precancerous lesions, oral cancer and other oral cavity mucosal disorders
ES2656237T3 (es) 2011-04-19 2018-02-26 Alfama, Inc. Moléculas liberadoras de monóxido de carbono y usos de las mismas
EP2734235B1 (de) 2011-07-21 2017-03-22 Alfama, Inc. Kohlenmonoxidfreisetzende rutheniummoleküle und ihre verwendungen
WO2014063134A1 (en) 2012-10-19 2014-04-24 New York University Methods for inhibiting osteolysis
BR112016000809A2 (pt) 2013-07-17 2017-08-22 Hibernation Therapeuitics A Kf Llc Método para tratar infecção, sepsia e lesão
JP2013234200A (ja) * 2013-08-19 2013-11-21 Hibernation Therapeutics Ltd 組織維持の改善
US10092591B2 (en) 2014-02-27 2018-10-09 University Of Alaska Fairbanks Methods and compositions for the treatment of ischemic injury to tissue using therapeutic hypothermia
CN103893205B (zh) * 2014-04-15 2016-03-09 青岛大学附属医院 一种包含利多卡因和腺苷的心脏停搏液及其制备方法
CA2947711A1 (en) * 2014-05-01 2015-11-05 Catherine E. Berry A modified single dose, microplegic approach to cardioplegia for the adult heart
US9501418B2 (en) * 2014-06-26 2016-11-22 HGST Netherlands B.V. Invalidation data area for cache
US9913903B2 (en) * 2015-08-06 2018-03-13 Grifols Worldwide Operations Limited Method for the treatment or prevention of infection-related immune conditions using a composition comprising IgM
CN109769797B (zh) * 2017-11-13 2024-09-10 合肥华琪生物工程有限公司 一种器官保存液
US12471592B2 (en) 2021-08-18 2025-11-18 Reelabs Private Limited Cytoprotective compositions for short-term cells storage and transportation without cryopreservation and deep freezing

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU878297A1 (ru) 1978-05-03 1981-11-07 Научно-Исследовательский Институт Трансплантологии И Искусственных Органов Состав дл сохранени жизнеспособности оперируемого сердца
US4798824A (en) * 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5006512A (en) 1987-10-02 1991-04-09 Tsuyoshi Ohnishi Therapeutic usages of inhibitors for a potassium efflux channel
US5256770A (en) * 1990-04-09 1993-10-26 Schering Ag Oxidation resistant thrombomodulin analogs
DE3926287A1 (de) * 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5145771A (en) * 1990-04-12 1992-09-08 The University Of North Carolina At Chapel Hill Rinse solution for organs and tissues
US5206222A (en) 1991-05-22 1993-04-27 Vanderbilt University Methods for the reduction of myocardial reperfusion injury
CN1057192A (zh) 1991-06-30 1991-12-25 汪庆富 风油精聚胺酯海绵的制备工艺
US5407793A (en) 1991-10-18 1995-04-18 University Of Pittsburgh Of The Commonwealth System Of Higher Education An aqueous heart preservation and cardioplegia solution
RU2025973C1 (ru) * 1992-02-10 1995-01-09 Научно-производственное предприятие "Биофарм" Раствор для консервации живых органов
US5370989A (en) * 1992-04-03 1994-12-06 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5405742A (en) * 1993-07-16 1995-04-11 Cyromedical Sciences, Inc. Solutions for tissue preservation and bloodless surgery and methods using same
US5679706A (en) * 1994-09-30 1997-10-21 Bristol-Myers Squibb Company Combination of a potassium channel activator and an antiarrhythmic agent
US5554497A (en) * 1994-12-12 1996-09-10 Charlotte-Mecklenburg Hospital Authority Cardioplegic solution for arresting an organ
US5656420A (en) * 1995-02-24 1997-08-12 University Of Kentucky Research Foundation Method for employing the delta opioid dadle to extend tissue survival time during ischemia
JP3875295B2 (ja) * 1995-11-30 2007-01-31 功 竹内 心筋保護液
CA2279651A1 (en) 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
IT1297886B1 (it) * 1997-02-28 1999-12-20 Carmine Antropoli Nifedipina per uso topico
CA2295195C (en) 1997-06-18 2009-12-15 Aderis Pharmaceuticals, Inc. Compositions and methods for preventing restenosis following revascularization procedures
CN1057192C (zh) 1997-09-10 2000-10-11 上海长征医院 一种配制多器官保存液的方法
US6011017A (en) 1998-04-15 2000-01-04 Cypros Pharmaceutical Corp. Method of reducing pulmonary hypertension and atrial fibrillation after surgery using cardiopulmonary bypass
KR100762018B1 (ko) 1998-07-16 2007-10-04 메모리얼 슬로안-케터링 캔서 센터 오피오이드 진통제 및 엔엠디에이 길항제를 함유하는 국소조성물
KR100269540B1 (ko) 1998-08-28 2000-10-16 윤종용 웨이퍼 상태에서의 칩 스케일 패키지 제조 방법
EP1041970B1 (de) 1998-10-23 2013-07-03 Polyheal Ltd. Zusammensetzungen von mikrosphaeren zur wundheilung
US6358208B1 (en) 1998-11-21 2002-03-19 Philipp Lang Assessment of cardiovascular performance using ultrasound methods and devices that interrogate interstitial fluid
PL351484A1 (en) * 1999-03-23 2003-04-22 Univ James Cook Organ arrest, protection and preservation
US6586413B2 (en) * 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
WO2001054679A2 (en) 2000-01-27 2001-08-02 Children's Hospital Research Foundation Transdermal composition containing an anesthetic and a vasodilator agent
JP2001261575A (ja) 2000-03-13 2001-09-26 General Hospital Corp 血管収縮を調節する方法とその組成物
US6569615B1 (en) 2000-04-10 2003-05-27 The United States Of America As Represented By The Department Of Veteran's Affairs Composition and methods for tissue preservation
CA2407683C (en) 2000-04-28 2010-04-13 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
DE60121458T2 (de) 2000-09-26 2007-02-15 Medtronic, Inc., Minneapolis Medizinische vorrichtung zur blutstromsteuerung
GB0028414D0 (en) 2000-11-22 2001-01-03 Univ Leeds Flush preservation solution
CA2474316A1 (en) 2002-01-29 2003-08-07 Cognetix, Inc. Kappa-pviia-related conotoxins as organ protectants
ATE418991T1 (de) 2002-04-18 2009-01-15 Cv Therapeutics Inc Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
AUPS312602A0 (en) 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US20040229780A1 (en) * 2002-09-20 2004-11-18 Olivera Baldomero M. KappaM-conopeptides as organ protectants
US6921633B2 (en) 2002-11-18 2005-07-26 Biolife Solutions Incorporated Methods and compositions for the preservation of cells, tissues or organs in the vitreous state
US20040167226A1 (en) 2002-12-16 2004-08-26 Serafini Tito A. Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same
GB2436255B (en) 2002-12-23 2007-11-28 Global Cardiac Solutions Pty L Organ preconditioning, arrest, protection, preservation and recovery
CA2551169A1 (en) 2002-12-23 2004-07-08 Global Cardiac Solutions Pty Ltd Organ preconditioning, arrest, protection, preservation and recovery
US6992075B2 (en) 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
EP1628649A4 (de) 2003-06-02 2010-06-02 Samaritan Pharmaceuticals Inc Neuroprotektive benzoat- und benzamid-verbindungen
US7049309B2 (en) * 2003-10-14 2006-05-23 Bristol-Myers Squibb Company 3-Thia-4-arylquinolin-2-one potassium channel modulators
US20080097385A1 (en) 2004-12-22 2008-04-24 Jakob Vinten-Johansen Therapeutic Adjuncts to Enhance the Organ Protective Effects of Postconditioning
WO2007030198A2 (en) 2005-07-11 2007-03-15 Human Biosystems Improved methods and solutions for storing donor organs
AU2006345361B2 (en) 2006-05-29 2014-04-10 Hibernation Therapeutics, A Kf Llc Improved tissue maintenance
JP2009544628A (ja) 2006-07-25 2009-12-17 ハイバーネイション セラピューティクス リミテッド 外傷治療
EP2173353B1 (de) 2007-03-02 2015-05-06 Hibernation Therapeutics, a KF LLC Zusammensetzung mit Adenosin und Lignocain
CN100423638C (zh) 2007-03-22 2008-10-08 南京吉脉生物技术有限公司 一种器官保存液及其制备方法
US20100256083A1 (en) 2007-07-25 2010-10-07 Hibernation Therapeutics Limited Organ protection, preservation and recovery

Also Published As

Publication number Publication date
PL351484A1 (en) 2003-04-22
JP4949558B2 (ja) 2012-06-13
CA2364687C (en) 2014-11-18
NO20110807L (no) 2001-11-07
NO331669B1 (no) 2012-02-20
US7223413B2 (en) 2007-05-29
EP1168912B1 (de) 2007-05-09
US20100298254A1 (en) 2010-11-25
US20050171050A1 (en) 2005-08-04
NO20014557L (no) 2001-11-07
US7749522B2 (en) 2010-07-06
EP2359688B1 (de) 2015-05-27
US20130184231A1 (en) 2013-07-18
US20160263141A1 (en) 2016-09-15
JP2002539224A (ja) 2002-11-19
US9320753B2 (en) 2016-04-26
HK1161035A1 (en) 2012-08-24
EP2359688A1 (de) 2011-08-24
US20090298789A1 (en) 2009-12-03
ES2287001T3 (es) 2007-12-16
US20070270372A1 (en) 2007-11-22
NO20014557D0 (no) 2001-09-19
MXPA01009552A (es) 2003-08-19
US6955814B1 (en) 2005-10-18
WO2000056145A1 (en) 2000-09-28
EP1168912A4 (de) 2002-07-31
EP1790223A1 (de) 2007-05-30
IL145552A0 (en) 2002-06-30
CA2364687A1 (en) 2000-09-28
DE60034778D1 (de) 2007-06-21
BR0010653A (pt) 2002-02-05
TR200103235T2 (tr) 2002-01-21
CN1344135A (zh) 2002-04-10
KR20020001797A (ko) 2002-01-09
NZ514515A (en) 2003-11-28
DE60034778T2 (de) 2008-01-31
EP1168912A1 (de) 2002-01-09

Similar Documents

Publication Publication Date Title
ATE361667T1 (de) Stoppen, schützen und konservieren von organen
TR200002855T2 (tr) Raloksifenin solunum yolu ile veya burundan uygulanması.
BR0014384A (pt) Compostos para o tratamento da isquémia
DK1033981T3 (da) Formuleringer og fremgangsmåder til nedsættelse af antineoplastiske midlers toksicitet
GT199700009AA (es) Terapia combinada para la osteoporosis
BR9910180A (pt) Composição farmacêutica, processos para o tratamento de uma condição associada com a transmissão reduzida de nicotina, para identificação de um modulador positivo de um agonista receptor nicotìnico e para identificação de um composto, composto, e, uso de um modulador positivo de um agonista receptor nicotìnico
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
BR0007487A (pt) Difenil-uréias substituìdas com w-carbóxi-arilas como inibidores de raf cinase
BR0314356A (pt) Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
NO971192D0 (no) Fremgangsmåter for avlevering av materialer inn i huden, og sammensetninger som blir anvendt
ATE212846T1 (de) Bisphosphonat und anti-resorption agentien, enthaltende zusammensetzungen zur hemmung der knochenschwund
ATE287707T1 (de) Injizierbare propofol-formulierungen
ATE357928T1 (de) Pharmazeutische zusammensetzung für thrombinpeptidderivaten
BR0103169A (pt) Composição farmacêutica para o tratamento do distúrbio de hiperatividade de déficit de atenção (adhd)
ES2181017T3 (es) Composicion farmaceutica que contiene una sustancia promotora de osteogenesis y un polietilenglicol.
BR0311898A (pt) Tratamento de associação para depressão e ansiedade com antagonistas de nk1 e nk3
CY1106449T1 (el) Βελτιωμενη μεθοδος για εκριζωση του helicobacter pylori
DK1303278T3 (da) Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
AR029648A1 (es) El uso de un agonista de rar
BR0103913A (pt) Tratamento de combinação para depressão e ansiedade
AR030140A1 (es) Composiciones derivadas de la 2-piridinamina y metodos relacionados
BR0214159A (pt) Sistema farmacêutico radiopaco de liberação prolongada
DK0764023T3 (da) Forbindelser og præparater til administrering via oral inhalation eller insufflation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties